Clinical Study

Tak-981-1501- Phase 1/2 Study Of Tak-981 In Combination With Rituximab In Patients With Relapsed/Refractory Cd20-Positive Non-Hodgkin Lymphoma

Posted Date: May 7, 2021

  • Investigator: Emily Curran
  • Specialties: Cancer, Lymphoma, Oncology
  • Type of Study: Drug

The purpose of this study is to determine the safety, tolerability and to establish the recommended Phase 2 dose (RP2D) of TAK-981 in combination with rituximab in participants with r/r CD20+ Non-Hodgkins lymphoma in Phase 1, and to evaluate the efficacy of TAK-981 in combination with rituximab in select r/r CD20+ NHL indications in Phase 2. The primary outcome for phase 1 is incidence of emergent adverse events, and the primary outcome measured for phase 2 is Overall Response Rate.


Ecog 0-2, Adequate Organ Function Per Protocol, Have At Least 1 Bidimensionally Measurable Lesion, No Central Nervous System Lymphoma; Active Brain Or Leptomeningeal Metastases, No Prior Allogeneic Hematopoietic Stem-Cell Transplantation, No Other Malignancy Within 3 Years, No Active, Uncontrolled Autoimmune Disease Requiring >20 Mg Of Prednisone Or Equivalent, No Chronic Hepatitis B/C, No Significant Medical Diseases Or Conditions, As Assessed By The Investigators And Sponsor That Would Substantially Increase The Risk-Benefit Ratio Of Participating In The Study.


Lymphoma, Nhl

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.